Thinking beyond the sequence: CAR-T cell therapy litigation at the UPC (2seventy bio v Johnson & Johnson, UPC_CFI_029/2026)
The loss of market share we are already seeing for on-market cell therapy products is a result of in-class competitors for the same target a...
Dr Rose Hughes -
Monday, August 17, 2026
Thinking beyond the sequence: CAR-T cell therapy litigation at the UPC (2seventy bio v Johnson & Johnson, UPC_CFI_029/2026)
Reviewed by Dr Rose Hughes
on
Monday, August 17, 2026
Rating:
Reviewed by Dr Rose Hughes
on
Monday, August 17, 2026
Rating: